Medplus Health Services Q4 FY26 Results: PAT Rs 17 Cr
- May 21, 2026
- Posted by: Kashish Aggarwal
- Category: News
Medplus Health Services Q4 FY26 results were declared on May 20, 2026. The company reported PAT of Rs 17 crore for the quarter ended March 31, 2026, up 21% YoY compared to Rs 14 crore in Q4 FY25. Revenue from operations stood at Rs 248 crore, up 22% YoY. Gross profit was Rs 22 crore (+29%). Results are on a Standalone basis. Medplus Health Services is a Pharmacy Retail company listed on Indian stock exchanges.
Click Here – Get Free Investment Predictions
Medplus Health Services Q4 FY26 Financial Highlights
| Metric | Q4 FY26 (Rs Cr) | Q4 FY25 (Rs Cr) | YoY Change |
|---|---|---|---|
| Revenue | 248 | 202 | +22% |
| Gross Profit | 22 | 17 | +29% |
| Net Profit | 17 | 14 | +21% |
| Basis | Standalone | ||
Note: Medplus Health Services Q4 FY26 results declared May 20, 2026. Verify from BSE/NSE audited filings before making investment decisions.
Medplus Health Services Q4 FY26 Performance Analysis
The Medplus Health Services Q4 FY26 results reflect the company’s performance in the January to March 2026 quarter. The quarter demonstrates stable operational delivery. Medplus Health Services operates in the Pharmacy Retail sector, a segment supported by India’s GDP growth above 6.5% and domestic demand momentum in FY26.
The 21% YoY PAT growth to Rs 17 crore in Medplus Health Services Q4 FY26 reflects operational improvements and favourable demand conditions.
Screen the best stocks on the Univest Screener.
Key Factors Driving Medplus Health Services Q4 FY26 Results
Revenue Performance
Medplus Health Services Q4 FY26 revenue of Rs 248 crore was up 22% YoY. Strong double-digit revenue growth reflects market share gains and healthy end-market demand in the Pharmacy Retail space.
Profitability and Margins
The Medplus Health Services Q4 FY26 PAT of Rs 17 crore (up 21% YoY) reflects stable earnings delivery in a competitive environment.
India Macro Tailwinds Q4 FY26
The January to March 2026 quarter was supported by India’s robust macroeconomic environment with GDP above 6.5%, government capex continuity at Rs 11.21 lakh crore in the Union Budget FY27, and strong domestic consumption. The Reserve Bank of India’s accommodative policy stance supported credit and demand conditions. For Medplus Health Services, operating in the Pharmacy Retail sector, these macro conditions provided a constructive backdrop during the quarter ended March 31, 2026.
FY27 Outlook
Following Medplus Health Services Q4 FY26 results, investor focus will shift to FY27 revenue guidance, margin improvement roadmap, capital allocation plans, and management commentary on demand visibility. The Pharmacy Retail sector continues to benefit from India’s structural growth, rising consumption, and investment cycle. Sustaining the growth momentum and expanding margins will be the key priorities for management in FY27.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Frequently Asked Questions on Medplus Health Services Q4 FY26
What is Medplus Health Services Q4 FY26 net profit?
Ans. Medplus Health Services Q4 FY26 PAT of Rs 17 crore, up 21% YoY from Rs 14 crore in Q4 FY25. Results declared May 20, 2026 on a Standalone basis.
What is Medplus Health Services Q4 FY26 revenue?
Ans. Medplus Health Services Q4 FY26 revenue was Rs 248 crore, up 22% YoY. Gross profit was Rs 22 crore (+29%).
When were Medplus Health Services Q4 FY26 results declared?
Ans. Medplus Health Services Q4 FY26 results were declared on May 20, 2026, at the board of directors meeting approving audited financial statements for Q4 and full-year FY26.
Is Medplus Health Services a good investment after Q4 FY26 results?
Ans. Investment decisions require individual assessment of fundamentals, valuation, and risk tolerance. This article is for educational purposes. Consult a SEBI-registered financial advisor before investing in Medplus Health Services.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Verify all figures from BSE/NSE filings. Consult a SEBI-registered financial advisor.
